BioPharmSignal logoBioPharmSignal

Biotech News

Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan

Artivion (AORT)ArtivionEarnings

First Quarter & Recent Business Highlights: Achieved revenue of $116.3 million in the first quarter of 2026 versus $99.0 million in the first quarter of 2025, an increase of 18% on a GAAP basis and 12% on a non-GAAP constant currency basis Net income for the first quarter of 2026 was $1.4 million,

Related news

AORTArtivion2026-07-23 20:10 EST

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results

AORTArtivion2026-08-06 20:05 EST

Artivion Reports Second Quarter 2026 Financial Results

PLSEPulse Biosciences2026-08-06 20:05 EST

Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results

DNLIDenali Therapeutics2026-08-06 20:01 EST

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

AEMDAethlon Medical2026-08-05 12:01 EST

Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 13, 2026

ACHCAcadia Healthcare2026-07-28 20:05 EST

Acadia Healthcare Announces Second Quarter 2026 Results and Updates Full Year 2026 Financial and Cash Flow Guidance

DNLIDenali Therapeutics2026-07-27 20:01 EST

Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026

RXSTRxSight2026-07-06 20:15 EST

RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement

XAIRBeyond Air2026-06-26 11:00 EST

Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update

TMCITreace Medical Concepts2026-08-07 11:05 EST

Treace Medical Concepts Reports Second Quarter 2026 Financial Results

View all latest news

Artivion

Aortic-Disease Technologies Artivion develops medical devices and implantable tissues for complex aortic and cardiac surgery. Its portfolio is designed around the needs of cardiac and vascular surgeons treating life-threatening aortic disease. Surgical Products The company supplies aortic stent grafts, surgical adhesives, mechanical...

Recent company news

AORTArtivion2026-08-06 20:05 EST

Artivion Reports Second Quarter 2026 Financial Results

AORTArtivion2026-07-28 20:10 EST

Artivion to Participate in Upcoming Investor Conferences

AORTArtivion2026-07-23 20:10 EST

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results

AORTArtivion2026-06-29 11:00 EST

Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis

AORTArtivion2026-06-10 20:10 EST

Artivion to Participate in the 2026 Truist Securities MedTech Conference

Stock data

Close
26.57 USD
Market cap
991.26M USD
Exchange
NYSE
Sector
MedTech
Location
United States